Asymptomatic Microhematuria in Adults: Risk-Stratified Evaluation, Diagnostic Yield and Strategies to Avoid Unnecessary Testing

Abstract

Introduction and Purpose. Asymptomatic microhematuria is a common finding in adults, but the probability of clinically significant genitourinary malignancy varies considerably between patients. This review evaluates current approaches to microhematuria, focusing on risk stratification, diagnostic yield, and strategies that may reduce unnecessary invasive or imaging-based investigations.

Materials and Methods. A structured narrative review of PubMed/MEDLINE was performed and supplemented by current clinical practice guidelines and relevant systematic reviews, meta-analyses, and original studies. Publications from January 2015 to August 2026 were primarily considered, with earlier landmark studies included when relevant.

Results. Current evidence supports risk-based rather than uniform evaluation. Patients at very low risk can often be managed initially with repeat urinalysis, whereas cystoscopy and upper urinary tract imaging are increasingly justified as malignancy risk rises. Ultrasonography provides an appropriate first-line imaging option in many intermediate-risk patients, while CT urography remains important in higher-risk settings. Urine cytology and molecular urine-based markers may help refine decisions in selected intermediate-risk patients but cannot broadly replace cystoscopy. After a complete negative evaluation, subsequent malignancy detection is uncommon, and routine repeated invasive investigation has a low diagnostic yield.

Conclusions. Risk-stratified evaluation can reduce unnecessary testing while maintaining more intensive assessment for patients with a meaningful probability of malignancy. Further refinement of risk models and prospective validation of biomarker-guided pathways may allow more individualized diagnostic strategies.